SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates

Gregory A. Poland, Inna G. Ovsyannikova, Richard B. Kennedy

Research output: Contribution to journalReview articlepeer-review

26 Scopus citations

Abstract

Understanding immune responses to severe acute respiratory syndrome coronavirus 2 is crucial to understanding disease pathogenesis and the usefulness of bridge therapies, such as hyperimmune globulin and convalescent human plasma, and to developing vaccines, antivirals, and monoclonal antibodies. A mere 11 months ago, the canvas we call COVID-19 was blank. Scientists around the world have worked collaboratively to fill in this blank canvas. In this Review, we discuss what is currently known about human humoral and cellular immune responses to severe acute respiratory syndrome coronavirus 2 and relate this knowledge to the COVID-19 vaccines currently in phase 3 clinical trials.

Original languageEnglish (US)
Pages (from-to)1595-1606
Number of pages12
JournalThe Lancet
Volume396
Issue number10262
DOIs
StatePublished - Nov 14 2020

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates'. Together they form a unique fingerprint.

Cite this